PIK3CA 변이 호르몬 수용체 양성 진행성 유방암에 대한 Alpelisib

André 등(수요일)이 이 질문을 연구했다.

www.synapsesocial.com/papers/699ea8a3d8a7e1a4e1facfe4 — DOI: https://doi.org/10.1056/nejmoa1813904

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials· 2014 · 495 citations
2. An Audit Strategy for Progression-Free Survival· 2011 · 27 citations
3. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.· 2018 · 140 citations
4. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status· 2014 · 1,484 citations
5. Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study· 2009 · 199 citations